Molina Healthcare Inc. (NYSE:MOH) shares have collapsed in 2026 following the fourth-quarter earnings miss that has sent its technical indicators into a tailspin. It reported a surprising adjusted loss of $2.75 per share, while Wall Street was expecting a profit of $0.34. Following the earnings release on Feb. 5, Molina’s stock plummeted more than 30% in a single session, touching a 52-week low of $121.06.
Technical Indicators Crater Following Earnings Shock
This price action has decimated the stock’s Benzinga Edge rankings, where its momentum score collapsed from 14.04 to a bottom-tier 5.72 week-on-week. The stock is now down 24.16% year-to-date, according to recent market data. MOH maintains a weaker price trend over the long, short, and medium terms, with a strong value ranking as per Benzinga's Edge Stock Rankings.
Burry's ‘Peanut Butter And Bananas' Bet Sours
The collapse represents a significant blow to “Big Short” investor Michael Burry, who recently reaffirmed a massive contrarian position in the stock. Burry likened his long MOH/short PLTR pair trade to “peanut butter and bananas,” comparing Molina to a young GEICO and betting on its Medicaid resilience.
Despite the current 27% loss on his estimated purchase price, Burry maintains that the market’s reaction is overly harsh; however, that's easy for him to say when he's not dealing with daily trader sentiment or liquidity concerns pounding at their doors.
The ‘Trough Year’ Outlook
The fourth-quarter loss was largely attributed to $2.00 per share in unfavorable retroactive revenue adjustments in California and soaring medical costs across Medicare and Marketplace segments—classic red flags signaling trouble ahead.
CEO Joseph Zubretsky characterized 2026 as a “trough year” for margins, forecasting an adjusted EPS of at least $5.00—significantly lower than previous projections—as the company navigates away from traditional Medicare Advantage products.
What’s Going On With MOH Stock?
Shares of MOH have declined by 24.16% year-to-date while the S&P 500 was down just 0.33% during this time frame—a troubling divergence that could hint at deeper issues within Molina’s business model or operational execution.
The stock was down 19.98% over the last six months and an eye-watering 49.60% over the year; that ain't just volatility; it screams desperation among traders who are navigating through choppy waters here.
A seasoned trader might ask: What if this isn't just noise? What if it's indicative of systemic challenges within Molina?
Michael Burry's once-favorable outlook appears shaky against these stark realities—the kind of disconnect between projections and performance that usually triggers panic selling in these types of equities.
Bullish vs Bearish Sentiment
- Market watchers need to weigh potential recovery against ongoing headwinds like increased medical expenses and regulatory changes affecting revenue streams.
- The shift away from traditional Medicare Advantage products poses risks but could also open new avenues for growth if executed properly—if being key here!
This scenario often lays out clear paths for trading strategies; savvy investors will likely capitalize on rebounds while others flee into safer havens during uncertain times like this. However, if you're riding with Burry on this one, tread carefully—his 'peanut butter' bet may still be stuck in sticky territory while fundamentals crumble around it.
